An oral small molecule that activates GLP-1 receptors.
Chinese adults with overweight or obesity without diabetes
Study contextChina phase 3 obesity enrolled; results expected 2026.
Status sourceStatus & indications6.83% reported weight loss · 2.88% loss with placebo · 12 weeks
HDM1002 phase 2 obesity trial · Phase 2 · sponsor · 400 mg once daily · Other / incompletely specified
Evidence & limitationsAcross doses nausea40.4–71.7%, vomiting25.5–73.9%; events mainly during titration; 97.3% completed.
Safety contextA next milestone is not summarized for this therapy.
Milestone detailsStudy results apply to their own population, dose and analysis. They do not establish a ranking between therapies.
Each result belongs to its own study population, dose and analysis. Open a result for its chart, comparator, safety findings and limitations.
6.83% reported weight loss · 2.88% loss with placebo · 12 weeks
400 mg once daily
Chinese adults with overweight or obesity without diabetes
Least-squares mean percent change; formal estimand not stated. China phase 3 obesity enrolled; results expected 2026.
Across doses nausea40.4–71.7%, vomiting25.5–73.9%; events mainly during titration; 97.3% completed.
Limitations: Conference abstract; 400mgQD chosen among regimens including200mgBID.
Status in this atlas: China phase 3 obesity enrolled; results expected 2026. Status source
An oral small molecule that activates GLP-1 receptors.
What do these hormones do? GLP-1
No approved trade name verified. Conveglipron is the generic name and HDM1002 is its development code.
Huadong Medicine / Hangzhou Zhongmei Huadong Pharmaceutical · Originator and clinical developer; trials sponsored through its pharmaceutical subsidiary.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Chemical connectivity and stereochemistry of Conveglipron.
Shown: Active compound as represented in the named PubChem record; formulation excipients excluded.
A two-dimensional chemical diagram shows bonds and stereochemistry, not a measured three-dimensional shape.
PubChem, National Library of Medicine
PubChem CID 166540968Conveglipron · compound history across indications
Selected milestones only. Earlier studies may be missing; the first listed date should not be interpreted as the start of development.
Huadong's quarterly report records the first participant in the diabetes phase 3 program in August 2025; obesity phase 3 enrollment was also complete by the report.
SourceThe randomized 12-week trial reported dose-specific weight loss for oral HDM1002, including 400 mg once daily.
SourceSelected sources checked Sep 13, 2026. This is not an exhaustive history.
